Clinical Trial Update: Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a Phase 1/2 neoadjuvant study evaluating dupilumab plus cemiplimab in patients with early-stage resectable non-small cell lung cancer;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DUPIXENT (DUPILUMAB)
• Libtayo (cemiplimab)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING